Vectors based on autonomous parvoviruses: Novel tools to treat cancer?

Journal of Gene Medicine

Volumn 6, Issue SUPPL. 1, 2004, Pages

  Cornelis, Jan J ^a   Salomé, Nathalie ^a   Dinsart, Christiane ^a   Rommelaere, Jean ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cancer therapy; Cytokines; Oncolytic virus; Parvovirus; Toxins

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTIN; B7 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; ONCOLYTIC VIRUS; PARVOVIRUS VECTOR; THYMIDINE KINASE; VIRUS VACCINE;

ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL KILLING; DISEASE MODEL; GENE AMPLIFICATION; GENE EXPRESSION; GENE TRANSFER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MELANOMA; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS RECOMBINANT; ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; NEOPLASM;

ANIMALIA; DNA VIRUSES; PARVOVIRUS; RODENT PARVOVIRUSES; RODENTIA;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; PARVOVIRUS;

EID: 4344684036     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.502     Document Type: Review

References (87)

1. Berns KI. Parvoviridae: the viruses and their replication, In Fields Virology, Fields BN, Knipe DM, Howley PM, et al. (eds). Lipincott-Raven: Philadelphia, 1996; 2173-2197.
2. Jacoby RO, Ball-Goodrich LJ, Besselsen DG, et al. Rodent parvovirus infections. Lab Animal Sci 1996; 46: 370-380.
3. Rommelaere J, Cornelis JJ. Antineoplastic activity of parvoviruses. J Virol Methods 1991; 33: 233-250.
4. Ball-Goodrich LJ, Leland SE, Johnson EA, et al. Rat parvovirus type 1: the prototype for a new rodent parvovirus serogroup. J Virol 1998; 72: 3289-3299.
5. McKisic MD, Paturzo FX, Smith AL. Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions Transplantation 1996; 61: 292-299.
6. Toolan HW. Lack of oncogene effect of the H-viruses for hamsters. Nature 1967; 214: 1036.
7. Toolan HW, Rhode SL, Gierthy JF. Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors in Syrian hamsters by prior infection with H-1 virus. Cancer Res 1982; 42: 2552-2555.
8. Bergs VV. Rat virus-mediated suppression of leukemia induction by Moloney virus in rats. Cancer Res 1969; 29: 1669-1672.
9. Guetta E, Graziani Y, Tal J. Suppression of Ehrlich ascites tumors in mice by minute virus of mice. J Natl Cancer Inst 1986; 76: 1177-1180.
10. Dupressoir T, Vanacker, J-M, Cornelis JJ, et al. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res 1989; 49: 3203-3208.
11. Faisst S, Guittard D, Benner A, et al. Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection. Int J Cancer 1998; 75: 584-589.
12. Haag A, Kestler J, Menten P, et al. High efficient transduction of cytokines to human tumor cells by means of autonomous parvovirus vectors and their anti-tumor effect in nude mice. Hum Gene Ther 2000; 11: 597-609.
13. Giese N, Raykov Z, DeMartino L, et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther 2002; 9: 432-442.
14. Mousset S, Rommelaere J. Minute virus of mice inhibits cell transformation by simian virus 40. Nature 1982; 300: 537-539.
15. Ronchetti A, Rovere P, Iezzi G, et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells and cytokines. J. Immunol 1999; 163: 130-136.
16. Melcher A, Todryk S, Hardwick N, et al. Tumour immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Med 1998; 4: 581-587.
17. Palmer GA, Tattersall P. Autonomous parvoviruses as gene transfer vehicles. In Parvoviruses, from Molecular Biology to Pathology and Therapeutic Uses, vol. 4. Faisst S, Rommelaere J (eds). Contributions to Microbiology, Karger: Basel, 2000; 178-202.
18. Rommelaere J, Cornelis JJ. Autonomous parvoviruses. In Replication-Competent Viruses for Cancer Therapy, vol. 22. Driever PH, Rabkin SD (eds). Monographs Virology, Karger: Basel, 2001; 100-128.
19. Tsao J, Chapman MS, Agbandje M, et al. The three-dimensional structure of canine parvovirus and its functional implications. Science 1991; 251: 1456-1464.
20. Agbandje-McKenna M, Llamas-Sainz AL, Wang F, et al. Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure 1998; 6: 1369-1381.
21. Tullis GE, Burger LR, Pintel DJ. The minor capsid protein VP1 of the autonomous parvovirus minute virus of mice is dispensable for encapsidation of progeny single-stranded DNA but is required for infectivity. J Virol 1993; 67: 131-141.
22. Tattersall P, Cawte PJ, Shatkin AJ, Ward D. Three structural polypeptides coded for by minute virus of mice, a parvovirus. J Virol 1976; 20: 273-289.
23. Chapman MS, Rossmann MG. Single-stranded DNA protein interactions in canine parvovirus. Structure 1995; 3: 151-162.
24. Agbandje M, Kajigaya S, McKenna R, et al. The structure of human parvovirus B19 at 8A resolution. Virology 1994; 203: 106-115.
25. Hernando E, Llamas-Saiz AL, Foces-Foces C, et al. Biochemical and physical characterization of parvovirus minute virus of mice virus-like particles. Virology 2000; 267: 299-309.
26. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262: 114-117.
27. Parker JSL, Murphy WJ, Wang D, et al. Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J Virol 2001; 75: 3896-3902.
28. Suikkanen S, Sääjarvi K, Hirsimäki J, et al. Role of recycling endosomes and lysosomes in dynein-dependent entry of canine parvovirus. J Virol 2002; 76: 4401-4411.
29. Zádori Z, Szelei J, Lacoste MC, et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001; 1: 291-302.
30. Bashir T, Hörlein R, Rommelaere J, Wilwand K. Cyclin A activates the DNA polymerase δ-dependent elongation machinery in vitro: a parvovirus DNA replication model. Proc Natl Acad. Sci USA 2000; 97: 5522-5527.
31. Cotmore SF, Tattersall P. The autonomously replicating parvoviruses of vertebrates. Adv Virus Res 1987; 33: 91-174.
32. Rayet B, Lopez-Guerrero J-A, Rommelaere J, Dinsart C. Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J Virol 1998; 72: 8893-8903.
33. Ohshima T, Iwama M, Ueno Y, et al. Induction of apoptosis in vitro and in vivo by H-1 parvovirus infection. J Gen Virol 1998; 79: 3067-3071.
34. Moehler M, Blechacz B, Weiskopf N, et al. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H-1 and derived vectors. Cancer Gene Ther 2001; 8: 158-167.
35. Ran Z-H, Rayet B, Rommelaere J, Faisst S. Parvovirus H-1 induced cell death: influence of intracellular NAD consumption on the regulation of necrosis and apoptosis. Virus Res 1999; 65: 161-174.
36. Tattersall P, Shatkin AJ, Ward DC. Sequence homology between the structural polypeptides of minute virus of mice. J Mol Biol 1977; 111: 375-394.
37. Valle N, Maroto B, Almendral JM. Phosphorylation of the N-terminal domain of the major capsid protein determines efficient nuclear exit of the parvovirus MVM in transformed cells. 9th Parvovirus Workshop, Bologna, Italy, 2002; 49.
38. Lombardo E, Ramírez JC, Garcia J, et al. Complementary roles of multiple nuclear targeting signals in the capsid proteins of the parvovirus minute virus of mice during assembly and onset of infection. J Virol 2002; 76: 7049-7059.
39. Cotmore SF, D'Abramo MA, Ticknor CM, et al. Controlled conformational transitions in the MVM virion exposure the VP1 N-terminus and viral genome without particle disassembly. Virology 1999; 254: 169-181.
40. Willwand K, Hirt B. The major capsid protein VP2 of minute virus of mice (MVM) particles can form particles which bind to the 3′-terminal hairpin of MVM replicative-form DNA and package single-stranded viral progeny DNA. J Virol 1993; 67: 5660-5663.
41. Rhode SL III. Transactivation of parvovirus P38 promoter by the 76K noncapsid protein. J Virol 1985; 55: 886-889.
42. Caillet-Fauquet P, Perros M, Brandenburger A, et al. Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins. EMBO J 1990; 9: 2989-2995.
43. Li X, Rhode SL III. Mutation of lysine 405 to serine in the parvovirus H-1NS1 abolishes its function for viral DNA replication, late promoter trans activation and cytotoxicity. J Virol 1990; 64: 4654-4660.
44. Nüesch JPF, Dettwiler S, Corbau R, et al. Replicative functions of minute virus of mice NS1 protein are regulated in vitro by phosphorylation through protein kinase C. J Virol 1998; 72: 9966-9977.
45. Corbau R, Duverger V, Rommelaere J, et al. Regulation of MVM NS1 by protein kinase C: impact of mutagenesis at consensus phosphorylation sites on replicative functions and cytophatic effects. Virology 2000; 278: 151-167.
46. Naeger LK, Cater J, Pintel DJ. The small nonstructural protein (NS2) of the parvovirus minute virus of mice is required for efficient DNA replication and infectious virus production in a cell-type-specific manner. J Virol 1990; 64: 6166-6175.
47. Cotmore SF, D'Abramo AM Jr, Carbonell LF, et al. The NS2 polypeptide of parvovirus MVM is required for capsid assembly in murine cells. Virology 1997; 231: 267-280.
48. Eichwald V, Daeffler L, Klein M, et al. The NS2 proteins of parvovirus minute virus of mice are required for efficient nuclear egress of progeny virions in mouse cells. J Virol 2002; 76: 10 307-10 319.
49. Dinsart C, Cornelis J, Rommelaere J. Recombinant autonomous parvoviruses: new tools for the gene therapy of cancer? Chemistry Today 1996; 9: 32-38.
50. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
51. Harbour JW , Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Develop 2000; 14: 2393-2409.
52. Perros M, Deleu L, Vanacker J-M, et al. Upstream CREs participate in the basal activity of minute virus of mice promoter P4 and in its stimulation in ras-transformed cells. J Virol 1995; 69: 5506-5515.
53. Fuks F, Deleu L, Dinsart C, et al. Ras oncogene-dependent activation of the P4 promoter of minute virus of mice through a proximal P4 element interacting with the Ets family of transcription factors. J Virol 1996; 70: 1331-1339.
54. Gu Z, Kunz-Simon G, Rommelaere J, Cornelis J. Oncogenic transformation-dependent expression of a transcription factor NF-Y subunit. Mol Carcinogenesis 1999; 24: 294-299.
55. KIP-overexpressing cells versus serum-starved or growing cells. Mol Cell Biol 1998; 18: 409-419.
56. Deleu L, Pujol A, Faisst S, Rommelaere J. Activation of promoter P4 of the autonomous parvovirus minute virus of mice (MVM) at the early S phase is required for productive infection. J Virol 1999; 73: 3877-3885.
57. Kimsey PB, Engers HD, Hirt B, et al. Pathology of fibroblast- and lymphocyte-specific variants of minue virus of mice. J Virol 1986; 59: 8-13.
58. Russell SJ, Brandenburger A, Flemming CL, et al. Transformation-dependent expression of interleukine genes delivered by a recombinant parvovirus. J Virol 1992; 66: 2821-2828.
59. Dupont F, Tenenbaum L, Guo LP, et al. Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different tissue origins and its expression therein. J Virol 1994; 68: 1397-1407.
60. Brandenburger A, Coessens E, El Bakkouri K, Velu T. Influence of sequence and size of DNA on packaging efficiency of parvovirus MVM-based vectors. Hum Gene Ther 1999; 10: 1229-1238.
61. Kestler J, Neeb B, Struyf S, et al. Cis-requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum Gene Ther 1999; 10: 1619-1632.
62. Dupont F, Karim A, Dumon J-C, et al. A novel MVMp-based vector system specifically designed to reduce the risk of replication-competent virus generation by homologous recombination. Gen Ther 2001; 8: 921-929.
63. Olijslagers S, Dege AY, Dinsart, et al. Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. Cancer Gene Ther 2001; 8: 958-965.
64. Dupont F, Avalosse B, Karim A, et al. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector. Gene Ther 2000; 7: 790-796.
65. Wetzel K, Menten P, Opdenakker G, et al. Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts. J Gene Med 2001; 3: 326-337.
66. El Bakkouri K, Clément N, Velu T, Brandenburger A. Anti-tumour activity of recombinant parvovirus MVM/IL2 in immuno-competent mice. 8th Parvovirus Workshop, Mont-Tremblant, Canada. 2000; 208-209.
67. Gancberg D, Zeicher M, Bakkus M, et al. Oncoselective transduction of CD80 and CD86 in tumor cell lines using an autonomous recombinant parvovirus. Anti-cancer Res 2000; 20: 1825-1832.
68. Moehler M, Zeidler M, Schede J, et al. Analysis of tumor immunogenicity, stress protein expression and phagocytosis of parvovirus H-1-infected human melanoma cells. J Cancer Res Clin Oncol 2002; 128: 143-144.
69. Brandenburger A, Velu T. Autonomous parvovirus vectors: preventing the generation of wild-type or replication-competent virus. J Gene Med 2004; 6: this issue.
70. Wrzesinski C, Tesfay L, Salomé N, et al. Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant virus stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells. J Virol 2003; 77: 3851-3858.
71. Palmer GA, Constant S, Tattersall P. Sustained humoral immunity following single inoculation of a parvoviral vaccine vector. 9th Parvovirus Workshop, Bologna, Italy. 2002; 85.
72. Brown C, DiSumma FM, Rommelaere J, et al. Production of recombinant H-1 parvoviruses devoid of replication-competent particles. Hum Gene Ther 2002; 13: 2135-2145.
73. Avalosse B, Dupont F, Spegelaere P, et al. Method for concentrating and purifying recombinant autonomous parvovirus vectors designed for tumour-cell-targeted gene therapy. J Virol Methods 1996; 62: 179-183.
74. Brandenburger A, Russell S. A novel packaging system for the generation of helper-free oncolytic MVM vector stocks. Gene Ther 1996; 3: 927-931.
75. Clément N, Avalosse B, El bakkouri K, et al. Cloning and sequencing of defective particles derived from the autonomous parvovirus minute virus of mice for the construction of vectors with minimal cis-acting sequences. J Virol 2001; 75: 1284-1293.
76. Clément N, Velu T, Brandenburger A. Construction and production of oncotropic vectors, derived from MVM(p) that share reduced sequence homology with helper plasmids. Cancer Gene Ther 2002; 9 762-770.
77. El Bakkouri K, Clément Velu T, Brandenburger A. Amplification of MVM(p) vectors through serial infection of a new packaging cel line. Tumor Targeting 2000; 4: 210-217.
78. Melcher A, Gough M, Todryk S, et al. Apoptosis or necrosis for tumor immunotherapy: what's in a name? J Mol Med 1999; 77: 824-833.
79. Pardoll DM. Paracrine cytokine adjuvants. Ann Rev Immunol 1995; 13: 399-415.
80. Wetzel K, Menten P, van Damme J, et al. Parvovirus vector transduced MCP-3 reduces tumor growth rate in nude mice and prevents tumor formation in immunocompetent mice. 8th Parvovirus Workshop, Mont-Tremblant, Canada, 2000; 163-164.
81. Palmer GA, Tattersall P. MVM-based vectors for transducing human and murine T cells. 8th Parvovirus Workshop, Mont-Tremblant, Canada, 2000; 70-71.
82. Toolan HW, Saunders EL, Southam CM, et al. H-1 virus viremia in the human. Proc Soc Exp Biol Med 1965; 119: 711-715.
83. Le Cesne A, Dupressoir T, Janin N, et al. Intra-lesional administration of a live virus, parvovirus H-1 (PVH-1), in cancer patients: a feasibility study. Proc Ann Meet Am Soc Clin Oncol 1993; 12: 297.
84. Lang S, Raykov Z, Giese N, et al. Strong humoral but poor cellular immune response to MVMp in C57BL/6 mice. 9th Parvovirus Workshop, Bologna, Italy, 2002; 70.
85. Moehler M, Zeidler M, Schede J, et al. The oncolytic parvovirus H1 induces release of heat shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells. Cancer Gene Ther 2003; 10: 477-480.
86. Raykov Z, Legrand V, Homann H, et al. Transient suppression of transgene expression by means of antisense oligonucleotides: a method for the production of toxin-transducing recombinant viruses. Gene Ther 2002; 9: 358-362.
87. Malerba M, Daeffler L, Rommelaere J, Iggo RD. Replicating parvoviruses that target cancer cells. J Virol 2003; 77: 6683-6691.